SCHEMBL4515927

SCHEMBL4515927

CN(CCF)c1ccc(C=O)c(O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 2/20 0.42
TRIM24 O15164 1/20 0.42
TRIM33 Q9UPN9 1/20 0.42
MAPT P10636 7/20 0.40
APP P05067 3/20 0.40
SNCA P37840 1/20 0.40
ALDH1A1 P00352 8/20 0.39
GAA P10253 4/20 0.39
HTT P42858 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
THRB P10828 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KDM4E B2RXH2 4/20 0.38
CYBB P04839 3/20 0.38
NOX4 Q9NPH5 3/20 0.38
LMNA P02545 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147111 0.86 CYBB (0.49) TYRTRIM24TRIM33MAPTAPP
SCHEMBL11823877 0.84 TYR (0.42) TYRTRIM24TRIM33MAPTALDH1A1
SCHEMBL5729223 0.82 TYR (0.46) TYRTRIM24TRIM33MAPTALDH1A1
SCHEMBL10844181 0.82 TYR (0.47) TYRTRIM24TRIM33MAPTALDH1A1
SCHEMBL11740869 0.81 ALDH1A1 (0.42) TYRTRIM24TRIM33MAPTALDH1A1
SCHEMBL29446225 0.78 TYR (0.52) TYRTRIM24TRIM33MAPTAPP
SCHEMBL1001895 0.78 TYR (0.52) TYRTRIM24TRIM33MAPTAPP
SCHEMBL30665426 0.78 ALDH1A1 (0.47) TYRTRIM24TRIM33MAPTALDH1A1
SCHEMBL9189739 0.78 ALDH1A1 (0.47) TYRTRIM24TRIM33MAPTALDH1A1
SCHEMBL22031855 0.77 TYR (0.43) TYRTRIM24TRIM33MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569337-B2 Labeling brain tissues in vivo or in vitro; 3-Benzothiazol-2-yl-7-[4-(2-fluoro-ethyl)-piperazin-1-yl]-chromen-2-one; diagnosis, monitoring the effectiveness of a therapeutic treatment and detecting histopathological hallmarks of Alzheimer's disease NOVARTIS AG (CH) 2009-08-04 US disclosed
EP-1483262-B1 COUMARINES USEFUL AS BIOMARKERS NOVARTIS AG (CH) 2007-11-14 EP disclosed
US-20050169837-A1 Coumarines useful as biomarkers NOVARTIS AG (CH) 2005-08-04 US disclosed
CN-1628114-A Coumarines useful as biomarkers NOVARTIS AG (CH) 2005-06-15 CN disclosed
EP-1483262-A1 COUMARINES USEFUL AS BIOMARKERS Novartis AG (CH) 2004-12-08 EP disclosed
WO-2003074519-A1 COUMARINES USEFUL AS BIOMARKERS NOVARTIS AG (CH) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050169837-A1 Coumarines useful as biomarkers CCNB1, CBR1, CYP1A1 TYR 3827/4885TRIM24 2606/4885TRIM33 2936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.